DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
Glutaminase as a metabolic target of choice to counter acquired resistance to Palbociclib by colorectal cancer cells
Several mechanisms of resistance of cancer cells to cyclin-dependent kinase inhibitors (CDKi) have been identified, including the upregulation of metabolic regulators such as glutaminase. However, whether such resistance mechanisms represent optimal targets has not been determined. Here, we have systematically analyzed metabolic reprogramming in colorectal cancer cells exposed to Palbociclib, a CDKi selectively targeting CDK4/6, or Telaglenastat, a selective glutaminase inhibitor. Through multiple approaches, we show that Palbociclib and Telaglenastat elicit complementary metabolic responses and are thus uniquely suited to counter the metabolic reprogramming induced by the reciprocal drug. As such, while Palbociclib induced reduced tumor growth in vivo, and Telaglenastat did not show a significant effect, the drug combination displayed a strong synergistic effect on tumor growth. Likewise, initial responses to Palbociclib were followed by signs of adaptation and resistance, which were prevented by combining Palbociclib with Telaglenastat. In conclusion, combination with Telaglenastat optimally forestalls acquired resistance to Palbociclib in cancer cells., This work was supported by I + D + i projects PID2023-150539OB-I00, PID2020-115051RB-I00, and PID2019-107139RB-C21, funded by MICIU/AEI/10.13039/501100011033/ European Commission FEDER funds “Una manera de hacer Europa”, the Interdisciplinary Platform-Global Health (Plataforma Temática Interdisciplinar-Salud Global, PTI-SG; SGL2103019), the Networked Researched Center on Liver and Digestive Diseases (Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas, CIBER-EHD; EHD20PI03 and CB17/04/00023), the Catalan Agency for Universities and Research (AGAUR) (2021-SGR-00350 and 2021-SGR-01490), ICREA Foundation (ICREA Academia award granted to M. Cascante) and The Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001223), the UK Medical Research Council (FC001223) and the Wellcome Trust (FC001223)., Peer reviewed
Proyecto:
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2023-150539OB-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2020-115051RB-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2019-107139RB-C21
DOI: http://hdl.handle.net/10261/421348, https://api.elsevier.com/content/abstract/scopus_id/105011157403
HANDLE: http://hdl.handle.net/10261/421348, https://api.elsevier.com/content/abstract/scopus_id/105011157403